Alogliptin, a dipeptidyl peptidase-4 inhibitor, regulates the atrial arrhythmogenic substrate in rabbits

Heart Rhythm

Volumn 12, Issue 6, 2015, Pages 1362-1369

  Yamamoto, Toshihiko ^a   Shimano, Masayuki ^a,b   Inden, Yasuya ^a   Takefuji, Mikito ^a   Yanagisawa, Satoshi ^a   Yoshida, Naoki ^a   Tsuji, Yukiomi ^b,c   Hirai, Makoto ^d   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^c NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^d NAGOYA UNIVERSITY   (Japan)

Author keywords

Atrial arrhythmogenic substrate; Atrial fibrillation; Atrial fibrosis; Atrialneovascularization; DPP 4inhibitor

Indexed keywords

ALOGLIPTIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; DIPEPTIDYL PEPTIDASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PIPERIDINE DERIVATIVE; URACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATRIAL FIBROSIS; CAPILLARY DENSITY; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; ENZYME PHOSPHORYLATION; HEART ATRIUM ARRHYTHMIA; HEART DILATATION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART MUSCLE CAPILLARY; HEART MUSCLE FIBROSIS; HEART PACING; HISTOPATHOLOGY; IMMUNOBLOTTING; MALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PLEURA EFFUSION; PRIORITY JOURNAL; SYSTOLIC DYSFUNCTION; VENTRICULAR TACHYPACING; ANALOGS AND DERIVATIVES; ANGIOGENESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; COMPLICATION; DRUG EFFECTS; ELECTROPHYSIOLOGY; ENDOTHELIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE; HEART ATRIUM; HEART VENTRICLE TACHYCARDIA; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; RABBIT; WESTERN BLOTTING;

ANIMALS; ATRIAL FIBRILLATION; BLOTTING, WESTERN; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; ECHOCARDIOGRAPHY; ELECTROPHYSIOLOGY; ENDOTHELIUM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE; HEART ATRIA; HEART FAILURE; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PIPERIDINES; RABBITS; TACHYCARDIA, VENTRICULAR; URACIL;

EID: 84930359275     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2015.03.010     Document Type: Article

References (31)

1. J. Heeringa, D.A. van der Kuip, A. Hofman, J.A. Kors, G. van Herpen, B.H. Stricker, T. Stijnen, G.Y. Lip, and J.C. Witteman Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study Eur Heart J 27 2006 949 953
2. T.J. Wang, M.G. Larson, D. Levy, R.S. Vasan, E.P. Leip, P.A. Wolf, R.B. D'Agostino, J.M. Murabito, W.B. Kannel, and E.J. Benjamin Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study Circulation 107 2003 2920 2925
3. D. Li, S. Fareh, T.K. Leung, and S. Nattel Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort Circulation 100 1999 87 95
4. B. Burstein, and S. Nattel Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation J Am Coll Cardiol 51 2008 802 809
5. M. Allessie, J. Ausma, and U. Schotten Electrical, contractile and structural remodeling during atrial fibrillation Cardiovasc Res 54 2002 230 246
6. K. Shinagawa, Y.F. Shi, J.C. Tardif, T.K. Leung, and S. Nattel Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs Circulation 105 2002 2672 2678
7. D. Li, K. Shinagawa, L. Pang, T.K. Leung, S. Cardin, Z. Wang, and S. Nattel Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure Circulation 104 2001 2608 2614
8. K. Kumagai, H. Nakashima, H. Urata, N. Gondo, K. Arakawa, and K. Saku Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation J Am Coll Cardiol 41 2003 2197 2204
9. T.A. Aksnes, R.E. Schmieder, S.E. Kjeldsen, S. Ghani, T.A. Hua, and S. Julius Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial) Am J Cardiol 101 2008 634 638
10. X. Du, T. Ninomiya, and B. de Galan ADVANCE Collaborative Group. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study Eur Heart J 30 2009 1128 1135
11. S.E. Mountantonakis, M.V. Grau-Sepulveda, D.L. Bhatt, A.F. Hernandez, E.D. Peterson, and G.C. Fonarow Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines-heart failure Circ Heart Fail 5 2012 191 201
12. M. Sauvé, K. Ban, M.A. Momen, Y.Q. Zhou, R.M. Henkelman, M. Husain, and D.J. Drucker Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice Diabetes 59 2010 1063 1073
13. Z. Shah, C. Pineda, T. Kampfrath, A. Maiseyeu, Z. Ying, I. Racoma, J. Deiuliis, X. Xu, Q. Sun, S. Moffatt-Bruce, F. Villamena, and S. Rajagopalan Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways Vascul Pharmacol 55 2011 2 9
14. C.-Y. Huang, C.M. Shih, and N.W. Tsao Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells Br J Pharmacol 167 2012 1506 1519
15. T. Shigeta, M. Aoyama, Y.K. Bando, A. Monji, T. Mitsui, M. Takatsu, X.W. Cheng, T. Okumura, A. Hirashiki, K. Nagata, and T. Murohara Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions Circulation 126 2012 1838 1851
16. B.M. Scirica, D.L. Bhatt, and E. Braunwald SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 369 2013 1317 1326
17. J. Feng, Z. Zhang, and M.B. Wallace Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV [published correction appears in J Med Chem 2008;51:4357] J Med Chem 50 2007 2297 2300
18. Y. Tsuji, T. Opthof, K. Yasui, Y. Inden, H. Takemura, N. Niwa, Z. Lu, J.K. Lee, H. Honjo, K. Kamiya, and I. Kodama Ionic mechanisms of acquired QT prolongation and torsades de pointes in rabbits with chronic complete atrioventricular block Circulation 106 2002 2012 2018
19. M. Shimano, Y. Tsuji, Y. Inden, K. Kitamura, T. Uchikawa, S. Harata, S. Nattel, and Murohara T. Pioglitazone a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure Heart Rhythm 5 2008 451 459
20. K. Kitamura, R. Shibata, Y. Tsuji, M. Shimano, Y. Inden, and T. Murohara Eicosapentaenoic acid prevents atrial fibrillation associated with heart failure in a rabbit model Am J Physiol Heart Circ Physiol 300 2011 H1814 H1821
21. M. Shimano, N. Ouchi, R. Shibata, K. Ohashi, D.R. Pimentel, T. Murohara, and K. Walsh Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response J Mol Cell Cardiol 49 2010 210 220
22. Z. Sonia, A.J. Blanca, M.V. Ruiz-Armenta, J.L. Miguel-Carrasco, M. Arévalo, M.J. Vázquez, A. Mate, and C.M. Vázquez L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression Biochem Pharmacol 85 2013 937 944
23. J.J. Gallagher Tachycardia and cardiomyopathy: the chicken-egg dilemma revisited J Am Coll Cardiol 6 1985 1172 1173
24. E.M. Zeisberg, O. Tarnavski, and M. Zeisberg Endothelial-to-mesenchymal transition contributes to cardiac fibrosis Nat Med 13 2007 952 961
25. K.E. Porter, N.A. Turner, D.J. O'Regan, and S.G. Ball Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin Cardiovasc Res 64 2004 507 515
26. A. Kazakov, R. Hall, P. Jagoda, K. Bachelier, P. Müller-Best, A. Semenov, F. Lammert, M. Böhm, and U. Laufs Inhibition of endothelial nitric oxide synthase induces and enhances myocardial fibrosis Cardiovasc Res 100 2013 211 221
27. M. Ishii, R. Shibata, K. Kondo, T. Kambara, Y. Shimizu, T. Tanigawa, Y.K. Bando, M. Nishimura, N. Ouchi, and T. Murohara Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitric-oxide synthase-dependent mechanism J Bio Chem 289 2014 27235 27245
28. K. Kumagai, H. Nakashima, and K. Saku The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model Cardiovasc Res 62 2004 105 111
29. A.D. Dobrian, Q. Ma, J.W. Lindsay, K.A. Leone, K. Ma, J. Coben, E.V. Galkina, and J.L. Nadler Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice Am J Physiol Endocrinol Metab 300 2011 E410 E421
30. Z. Shah, T. Kampfrath, and J.A. Deiuliis Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis Circulation 124 2011 2338 2349
31. R. Christopher, P. Covington, M. Davenport, P. Fleck, Q.A. Mekki, E.R. Wann, and A. Karim Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects Clin Ther 30 3 2008 513 527